Your browser doesn't support javascript.
loading
Development and Validation of Novel Z-360-Based Macromolecules for the Active Targeting of CCK2-R.
Vettorato, Elisa; Verona, Marco; Bellio, Greta; Croci, Stefania; Filadi, Riccardo; Bisio, Alessandra; Spessot, Eugenia; Andrighetto, Alberto; Maniglio, Devid; Asti, Mattia; Marzaro, Giovanni; Mastrotto, Francesca.
Afiliação
  • Vettorato E; Department of Pharmaceutical and Pharmacological Sciences, University of Padova, via Marzolo 5, 35131 Padova, Italy.
  • Verona M; Legnaro National Laboratories, Italian Institute of Nuclear Physics (INFN), viale dell'Università, 2, 35020 Legnaro (Padova), Italy.
  • Bellio G; Department of Pharmaceutical and Pharmacological Sciences, University of Padova, via Marzolo 5, 35131 Padova, Italy.
  • Croci S; Department of Pharmaceutical and Pharmacological Sciences, University of Padova, via Marzolo 5, 35131 Padova, Italy.
  • Filadi R; Clinical Immunology, Allergy, and Advanced Biotechnologies Unit, AUSL-IRCCS of Reggio Emilia, via Amendola 2, 42122 Reggio Emilia, Italy.
  • Bisio A; Department of Biomedical Sciences, University of Padova, via Ugo Bassi 58/B, 35131 Padova, Italy.
  • Spessot E; Neuroscience Institute, National Research Council (CNR), 35131 Padua, Italy.
  • Andrighetto A; Department of Cellular, Computational and Integrative Biology (CIBIO), University of Trento, via Sommarive 9, 38123 Trento, Italy.
  • Maniglio D; Department of Industrial Engineering and BIOtech Research Center, University of Trento, via Delle Regole 101, 38123 Trento, Italy.
  • Asti M; Legnaro National Laboratories, Italian Institute of Nuclear Physics (INFN), viale dell'Università, 2, 35020 Legnaro (Padova), Italy.
  • Marzaro G; Department of Industrial Engineering and BIOtech Research Center, University of Trento, via Delle Regole 101, 38123 Trento, Italy.
  • Mastrotto F; Radiopharmaceutical Chemistry Section, Nuclear Medicine Unit, AUSL-IRCCS of Reggio Emilia, Via Amendola 2, 42122 Reggio Emilia, Italy.
Mol Pharm ; 21(8): 3848-3865, 2024 Aug 05.
Article em En | MEDLINE | ID: mdl-38959127
ABSTRACT
The cholecystokinin type 2 receptor (CCK2-R) represents an ideal target for cancer therapy since it is overexpressed in several tumors and is associated with poor prognosis. Nastorazepide (Z-360), a selective CCK2-R antagonist, has been widely investigated as a CCK2-R ligand for targeted therapy; however, its high hydrophobicity may represent a limit to cell selectivity and optimal in vivo biodistribution. Here, we present three new fluorescent Z-360 derivatives (IP-002G-Rho, IP-002L-Rho, and IP-002M-Rho) in which nastorazepide was linked, through spacers bearing different saccharides (glucose (G), lactose (L), and maltotriose (M)), to sulforhodamine B. A fourth compound (IP-002H-Rho) with no pendant sugar was also synthesized as a control. Through two-dimensional (2D) and three-dimensional (3D) in vitro studies, we evaluated the compound association with and selectivity for CCK2-R-overexpressing cells (A431-CCK2-R+) vs CCK2-R-underexpressing cells (A431 WT). 2D in vitro studies highlighted a progressive increase of IP-002x-Rho association with A431-CCK2-R+ cells according to the linker hydrophilicity, that is, maltotriose > lactose > glucose > hydrogen, with IP-002M-Rho showing a 2.4- and a 1.36-fold higher uptake than IP-002G-Rho and IP-002L-Rho, respectively. Unexpectedly, IP-002H-Rho showed a similar cell association to that of IP-002L-Rho but with no difference between the two tested cell lines. On the contrary, association with A431-CCK2-R+ cells as compared to the A431 WT was found to be 1.08-, 1.14-, and 1.37-fold higher for IP-002G-Rho, IP-002L-Rho, and IP-002M-Rho, respectively, proving IP-002M-Rho to be the best-performing compound, as also confirmed by competition studies. Trafficking studies on A431-CCK2-R+ cells incubated with IP-002M-Rho suggested the coexistence of receptor-mediated endocytosis and simple diffusion. On the contrary, a high and selective uptake of IP-002M-Rho by A431-CCK2-R+ cells only was observed on 3D scaffolds embedded with cells, underlining the importance of 3D models in in vitro preliminary evaluation.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Receptor de Colecistocinina B Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Receptor de Colecistocinina B Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article